Biomarker Development for Metastatic Renal Cell Carcinoma: Omics, Antigens, T-cells, and Beyond

The treatment of metastatic renal cell carcinoma has evolved quickly over the last few years from a disease managed primarily with sequential oral tyrosine kinase inhibitors (TKIs) targeting the vascular endothelial growth factor (VEGF) pathway, to now with a combination of therapies incorporating i...

Descripción completa

Detalles Bibliográficos
Autores principales: Miron, Benjamin, Xu, David, Zibelman, Matthew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7712808/
https://www.ncbi.nlm.nih.gov/pubmed/33202724
http://dx.doi.org/10.3390/jpm10040225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7712808/
https://www.ncbi.nlm.nih.gov/pubmed/33202724
http://dx.doi.org/10.3390/jpm10040225

Ejemplares similares